BioCentury
ARTICLE | Finance

Refilling Alexion’s cupboard

Why Wilson takeout is a smart but small step towards filling Alexion’s pipeline

April 20, 2018 5:39 PM UTC

The first deal by Alexion Pharmaceuticals Inc.’s freshly rebuilt management team serves to amplify its biggest challenge -- it needs many more external assets to break its Soliris eculizumab dependence, and it may not have the financial firepower to buy them.

On April 11, the rare disease company announced it will acquire Swedish biotech Wilson Therapeutics AB for $855 million in cash, gaining access to a single asset, Decuprate bis-choline tetrathiomolybdate (WTX101) to treat Wilson’s disease...